Cardiff Oncology, Inc. (CRDF) stock
CRDFNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.85−0.04 (-4.46%)
Close on Nov 20, 2026Market cap $66.34MP/E –Yield –
Cardiff Oncology price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Cardiff Oncology's price to sales ratio was 103.2× on Nov 11, 2026, against 305.3× a year earlier. Over the last 5 years it ranged from 103.2× to 488.9×, with a median of 199.5×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 103.2× | −273.1 |
| 2025 | Dec 31, 2025 | 376.3× | +69.4 |
| 2024 | Dec 31, 2024 | 307.0× | +163.2 |
| 2023 | Dec 29, 2023 | 143.7× | −11.4 |
| 2022 | Dec 30, 2022 | 155.2× | +31.9 |
| 2020 | Jul 31, 2020 | 123.3× | +88.6 |
| 2019 | Dec 31, 2019 | 34.7× | +9.6 |
| 2018 | Dec 31, 2018 | 25.1× | −5.1 |
| 2017 | Dec 29, 2017 | 30.2× | −133.8 |
| 2016 | Dec 30, 2016 | 163.9× | −207.0 |
| 2015 | Oct 30, 2015 | 370.9× | +71.0 |
| 2014 | Dec 31, 2014 | 299.9× | +10.8 |
| 2013 | Dec 31, 2013 | 289.2× | −16.3 |
| 2012 | Dec 31, 2012 | 305.4× | – |
See a number that looks wrong?